section name header

Pronunciation

da-bi-GAT-ran

Classifications

Therapeutic Classification: anticoagulants

Pharmacologic Classification: thrombin inhibitors

Indications

BEERS REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: 3–7% absorbed following oral administration. Bioavailability of oral pellets higher than that of capsules in adults.

Distribution: Unknown.

Metabolism/Excretion: Of the amount absorbed, mostly excreted by kidneys (80%); 86% of ingested dose is eliminated in feces due to poor bioavailability.

Half-life: 12–17 hr.

Time/Action Profile

(effects on coagulation)

ROUTEONSETPEAKDURATION
POwithin hrsunknown2 days

†Following discontinuation, 3–5 days in renal impairment.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

GI: abdominal pain, diarrhea, dyspepsia, gastritis, esophageal ulceration, nausea.

Hemat: bleeding, thrombocytopenia.
Misc: (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)HYPERSENSITIVITY REACTIONS .

Interactions

Drug-Drug:

Route/Dosage

Do not interchange capsules and oral pellets on a milligram-to-milligram basis and do not combine these dose forms to achieve the total dose.

Reduction in Risk of Stroke/Systemic Embolism in Nonvalvular Atrial Fibrillation

Renal Impairment

Treatment of and Reduction in Risk of Recurrence of Deep Vein Thrombosis or Pulmonary Embolism

Capsules

Renal Impairment

Renal Impairment

Prevention of Deep Vein Thrombosis and Pulmonary Embolism Following Hip Replacement Surgery

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations: Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Pradaxa